Navigation Links
PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
Date:12/2/2013

ANNAPOLIS, Md., Dec. 2, 2013 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with consent from Theraclone. The agreement provided for the merger of a wholly-owned subsidiary of PharmAthene into Theraclone in an all-stock, merger-of-equals transaction. Accordingly, PharmAthene has cancelled the Special Meeting of Stockholders scheduled for December 3, 2013 and will pay Theraclone a $1 million termination fee.

Eric Richman, PharmAthene's President and Chief Executive Officer noted, "I would like to thank the employees and management of PharmAthene and Theraclone who have worked diligently on this transaction over the past several months. We at PharmAthene will continue to seek to identify opportunities to maximize value for our stockholders."

About PharmAthene

PharmAthene is a leading biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. PharmAthene's current biodefense portfolio includes the following product candidates:

  • SparVax® - a next generation recombinant protective (rPA) anthrax vaccine
  • rBChE bioscavenger - a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection

In addition, in May 2013, the Delaware Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery's finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case back to the Court of Chancery to reconsider the appropriate remedy and award of attorney's fees and expert witness costs in light of the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.

Forward-Looking Statements

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "will," "hopeful," "designed," "expect," "objective" or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements, except as required by law. Forward-looking statements include known and unknown risks and uncertainties, including, among others, the impact of the termination of the merger agreement between Pharmathene and Theraclone, including litigation previously announced relating to the proposed merger the Company's need for and ability to obtain additional financing; risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs; the award of government contracts to competitors; unforeseen safety issues; unexpected determinations that these product candidates prove not to be effective or capable of being marketed as products; as well as risks detailed from time to time in PharmAthene's annual report on Form 10-K and quarterly reports on Form 10-Q under the caption "Risk Factors" and in its other reports filed with the SEC. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
2. PharmAthene to Host Second Quarter 2013 Conference Call and Webcast on Wednesday, August 7, 2013
3. PharmAthene To Host First Quarter 2013 Conference Call And Webcast On Wednesday, May 8, 2013
4. PharmAthene Reports Year-End 2012 Financial And Operational Results
5. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
6. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
7. PharmAthene Reports Third Quarter 2012 Financial Results
8. PharmAthene Reports First Quarter 2012 Financial Results
9. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
10. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
11. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DES MOINES, Iowa , Feb. 22, 2017 Origin ... an agricultural biotechnology trait and seed provider, and Arcadia ... -based company that develops and commercializes agricultural productivity traits and ... of a key corn biotechnology product developed in China ... completion of global regulatory trials. ...
(Date:2/22/2017)... PHOENIX and SAN DIEGO ... Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion ... universal donor stem cell product through establishment of ... initiated research activities at the San Diego BioLabs ... Companies, Boehringer Ingelheim, Novartis, and Sanofi. ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, CloudMine, ... applications, announced a partnership with Redox, a leader in cloud-based healthcare integration and ... systems while keeping data secure in the cloud. , The digital health developers, ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... The medical ... for their use, in multiple areas of medicine, due to their differentiating characteristics. Stem ... and they have the ability to be induced to become tissue or organic-specific cells ...
Breaking Biology Technology:
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
(Date:1/18/2017)... 18, 2017 MedNet Solutions , ... the entire spectrum of clinical research, is proud ... year for the organization in terms of corporate ... eClinical products and services. The company,s exceptional achievements ... of iMedNet ™ ...
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
Breaking Biology News(10 mins):